{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:53:43Z","timestamp":1768985623579,"version":"3.49.0"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>In patients with chronic kidney disease (CKD), anemia develops gradually, which is primarily due to an inadequate synthesis of erythropoietin by the kidneys, as well as to iron disorders in the body, blood loss, shortened erythrocyte survival and inflammation. The currently accepted treatment employs iron, vitamin B12, folic acid supplementation and the use of erythropoiesis stimulants, which are administered only parenterally. Research is currently underway on the new erythropoiesis drugs that can be orally administered, i.e., hypoxia-inducible factor-propyl hydroxylase inhibitor (HIF-PHI) inhibitors which temporarily block propyl hydroxylase [PHD] catalysis and promote a transient increase in the expression of genes regulated by HIF, including kidney and liver erythropoietin [EPO]. Roxadustat is the first oral drug in this class and a potent HIF-PHD inhibitor, exerted to treat anemia in patients with CKD. In phase 1, 2 and 3 studies with CKD-affected patients, roxadustat was more effective to stimulate erythropoiesis for anemia correction than previously used drugs. Roxadustat can be orally given, unlike other erythropoiesis drugs with parenteral administration only, which grants roxadustat a considerable advantage. Our paper presents the results of studies with roxadustat applied for the treatment of anemia in CKD patients with or without dialysis. We are currently not yet able to know the exact role of roxadustat in the treatment of anemia in patients with CKD, but time will tell. It is possible that roxadustat has benefits an iron metabolism and cardiovascular risk.<\/jats:p>","DOI":"10.3390\/ijerph18041612","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T23:43:16Z","timestamp":1612914196000},"page":"1612","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Whether Prolyl Hydroxylase Blocker\u2014Roxadustat\u2014In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-3783","authenticated-orcid":false,"given":"W\u0142adys\u0142aw","family":"Grzeszczak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poniatowskiegostr., 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Szczyra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poniatowskiegostr., 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miros\u0142aw","family":"\u015anit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poniatowskiegostr., 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"ref_1","unstructured":"Podolak-Dawidziak, M. (2018). Anemia, Internal Medicine Szczeklik, Practical Medicine Krakow."},{"key":"ref_2","first-page":"23","article-title":"Cases and Observations Illustrative of Renal Disease, Accompanied with the Secretion of Albuminous Urine","volume":"49","author":"Bright","year":"1836","journal-title":"Med. Chir. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12325-017-0508-9","article-title":"A new approach to the management of anemia in CKD patients: A review on roxadustat","volume":"34","author":"Becker","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting hypoxia-inducible factors for the treatment of anemia in CKD patients","volume":"5","author":"Locatelli","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","article-title":"Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology","volume":"9","author":"Semenza","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1111\/hdi.12567","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomise, 6- to 19-week, open-Label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., and Thuss, U. (2014). Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111838"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomise placebo controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent CKD (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","unstructured":"FibroGen (2018, December 20). FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with CKD: Primary Efficacy Endpoints Met in All Three Studies, Non-Dialysis, Incident Dialysis, and Stable Dialysis Studies [Media Release]. Available online: http:\/\/investor.fibrogen.com\/phoenix.zhtml?c=253783&p=irol-newsArticle_print&ID=2381297."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-016-0422-y","article-title":"Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"36","author":"Adel","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00174.2010","article-title":"Hypoxic regulation of erythropoiesis and iron metabolism","volume":"299","author":"Haase","year":"2010","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_15","unstructured":"AstraZeneca (2018, December 20). Phase III OLYMPUS and ROCKIES Trials for Roxadustat Met Their Primary Endpoints in CKD Patients with Anaemia [Media Release]. Available online: https:\/\/www.astrazeneca.com\/media-centre\/pressreleases\/2018\/phase-iii-olympusand-rockies-trials-for-roxadustat-met-their-primary-endpoints-inchronic-kidney-disease-patients-with-anaemia20122018.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"Astellas Pharma (2018, September 20). Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in CKD (CKD) Patients with Anemia Not on Dialysis [Media Release]. Available online: https:\/\/www.astellas.com\/system\/files\/news\/2018-09\/180920_eg.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2016.02.010","article-title":"The hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) and warfarin in healthy volunteers: A pharmacokinetic and pharmacodynamic drug-drug interaction study","volume":"38","author":"Rijnders","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther. Apheresis Dial."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat Treatment of Chronic Kidney Disease Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: First Global Approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG4592): Correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1021\/jm400386j","article-title":"Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: Tricking the body into mounting orchestrated survival and repair responses","volume":"56","author":"Rabinowitz","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: Advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Del Balzo, U., Signore, P.E., Walkinshaw, G., Seeley, T., Brenner, M., Wang, Q., Guo, G., Arend, M., Flippin, L., and Chow, A. (2020). Nonclinical Characterization of the HIF-Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment for Anemia of Chronic Kidney Disease Fast Forward. J. Pharmacol. Exp. Ther.","DOI":"10.1124\/jpet.120.265181"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e14434","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Na\u00efve Chronic Kidney Disease Patients Not on Dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Provenzano, R., Tumlin, J., Zabaneh, R., Chou, J., Hemmerich, S., Neff, T.B., and Yu, K.P. (2020). Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. J. Clin. Pharmacol.","DOI":"10.1002\/jcph.1648"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pirri, D., Fragiadaki, M., and Evans, P. (2020). Diabetic atherosclerosis: Is there a role for the hypoxia-inducible factors?. Biosci. Rep., 40.","DOI":"10.1042\/BSR20200026"},{"key":"ref_31","first-page":"B5","article-title":"A phase 3, randomise, doubleblind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis (abstract no. TH-PO1153)","volume":"29","author":"Chen","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomise, double-blind, active-comparator (darberythropoietin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxiainducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101039","DOI":"10.1016\/j.molmet.2020.101039","article-title":"Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2a-dependent mechanism","volume":"41","author":"Riopel","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db14-0472","article-title":"HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction","volume":"63","author":"Karsikas","year":"2014","journal-title":"Diabetes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/ten.tea.2017.0484","article-title":"Acceleration of Diabetic Wound Healing with PHD2- and miR-210-Targeting Oligonucleotides","volume":"25","author":"Dallas","year":"2019","journal-title":"Tissue Eng."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00109-020-01903-0","article-title":"HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD","volume":"98","author":"Laitakari","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41374-019-0239-4","article-title":"Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet","volume":"99","author":"Saito","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sofue, T., Nakagawa, N., Kanda, E., Nagasu, H., Matsushita, K., Nangaku, M., Maruyama, S., Wada, T., Terada, Y., and Yamagata, K. (2020). Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (JCKD-DB). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236132"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/4\/1612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:21:27Z","timestamp":1760160087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/4\/1612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijerph18041612"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18041612","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}